Consistent with the reports in cervical cancers, we observed in the current study that PAX1 methylation testing had a 100% sensitivity and a 78.6% specificity in the detection of ESCC tumors, indicating that PAX1 methylation is a valuable biomarker for ESCC diagnosis. The gene discussed is PAX1; the disease is cervical carcinoma.